白癜风治疗药物—芦可替尼乳膏
A new drug for vitiligo—Ruxolitinib cream
黄帆 1门芳 2方翼2
作者信息
- 1. 北京大学人民医院 临床试验机构,北京 100044;北京大学医学部药学院 药事管理与临床药学系,北京 100191
- 2. 北京大学人民医院 临床试验机构,北京 100044
- 折叠
摘要
白癜风是一种慢性的皮肤自身免疫性疾病,主要表现为黑色素细胞丢失和皮肤出现白斑,导致患者产生多种心理疾病.芦可替尼乳膏是一种Janus激酶(JAK)1/2抑制剂,于2022年7月和2023年4月先后获得FDA和欧盟委员会批准,用于成人和12岁及以上儿童非节段性白癜风的局部治疗.大量临床研究表明,芦可替尼乳膏对白癜风的疗效明确、安全性和耐受性良好.本文对芦可替尼乳膏的作用机制及药理作用、药代动力学、临床疗效和安全性等进行综述,旨在为白癜风的临床治疗提供参考.
Abstract
Vitiligo is a chronic autoimmune skin disorder characterized by the loss of melanocytes and the appearance of white patches on the skin,which can lead to various psychological disorders in patients.Ruxolitinib cream,a topical formulation of selective JAK1/2 inhibitor,was successively approved by the Food and Drug Administration(FDA)in July 2022 and the European Commission(EC)in April 2023 for the local treatment of non-segmental vitiligo in adults and children aged over 12 years.Numerous clinical studies have demonstrated that Ruxolitinib cream has a definite therapeutic effect on vitiligo,with good safety and tolerability.This article provides a comprehensive review of the mechanism of action,pharmacological effects,pharmacokinetics,clinical efficacy,and safety of Ruxolitinib cream,aiming to offer a reference for the clinical treatment of vitiligo.
关键词
白癜风/芦可替尼乳膏/Janus激酶1/2抑制剂Key words
vitiligo/ruxolitinib cream/Janus kinase 1/2 inhibitor引用本文复制引用
出版年
2024
NETL
NSTL
万方数据